| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jia-Hui Yu, Jun Yu, Jin-Xin Yu, Lin-Feng Yang, Duan Yan, Yi Liu, Ju-Rui Xian and Peng-Sheng Yi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peng-Sheng Yi, PhD, Department of Hepato-Pancreato-Biliary II, National Clinical Key Specialty, Sub-center of National Clinical Research Center for Digestive Diseases, Sichuan Clinical Research Center for Digestive Diseases, Affiliated Hospital of North Sichuan Medical College, No. 1 Maoyuan South Road, Nanchong 637000, Sichuan Province, China. 13065256256@163.com |
| Key Words |
Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Lenvatinib; Prediction model; Retrospective study |
| Core Tip |
We summarized risk factors (number of tumors, microvascular invasion, Eastern Cooperative Oncology Group performance status, Child-Pugh stage, etc.) and protective factor (triple therapy) for unresectable HCC treated with TACE plus lenvatinib, constructed and validated prognostic models. In the validation set, area under the curve values of overall survival and progression-free survival, calibration curves, etc., confirmed their good performance, providing guidance for clinical practice. |
| Publish Date |
2025-11-14 00:56 |
| Citation |
<p>Yu JH, Yu J, Yu JX, Yang LF, Yan D, Liu Y, Xian JR, Yi PS. Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib. <i>World J Gastrointest Oncol</i> 2025; 17(11): 111814</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i11/111814.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i11.111814 |
